Understanding and Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan

Federal funding opportunity CDC-RFA-DD-26-0025 from Centers for Disease Control - NCBDDD (Department of Health and Human Services).

Program funding history

Synopsis

Who can apply

• For profit organizations other than small businesses
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Small businesses
• Independent school districts
• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
• Special district governments
• Private institutions of higher education
• City or township governments
• State governments
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Native American tribal organizations (other than Federally recognized tribal governments)
• County governments
• Public housing authorities/Indian housing authorities

Component A (Autism Data Collection and Dissemination): Applicants must have documented access to individual contact and eligibility data from participants in the Study to Explore Early Development (SEED) phases 1, 2, and/or 3 for all cohorts they propose to include in their recruitment pool to ensure successful completion of the data collection outlined in Component A of the NOFO. Therefore, applicants must either: 1) be the original entities that collected the original SEED data on children 2-5 years of age and their parents/caregivers, and therefore have the information needed to reach these individuals for the Survey to Promote Resources and Opportunities for aUtistic Teens and young adults (SPROUT); OR 2) have established collaborative agreements to work with the entities that originally collected contact information from SEED participants (i.e., former SEED recipients) so that they can reach the SEED participants for the data collection as outlined in Component A of the NOFO.Component B (Fragile X Data Collection): Applicants must provide evidence of access to clinic-based samples of children, adolescents, and adults (ages 0-40 years) with fragile X syndrome (FXS) full mutation diagnosis and demonstrate their ability and capacity to collect data on a minimum of 200 unique individuals in this population as outlined in Component B of the NOFO.Component C (Fragile X Data Dissemination): Applicants must demonstrate their ability and capacity to identify and reach populations of people with FXS and their families and communities, as well as healthcare providers, particularly those treating FXS patients, across the United States. Applicants must also demonstrate their ability to generate new communication and continually identify and update resources for the target populations, and well as quantify metrics of impact. Their history of outreach to these populations should include (but may not be limited to) evidence-based educational information, resources, and…

The official record

Similar grants

• Long-term health outcomes of people living with spina bifida
  CDC-RFA-DD-26-0222 · Centers for Disease Control - NCBDDD · closes October 26, 2026
• Maternal-Child Surveillance and Partnerships for Action, Results, and Knowledge
  CDC-RFA-DD-27-0028 · Centers for Disease Control - NCBDDD
• Surveillance and Case Control Study of Stillbirth and Birth Defects (SUCCSSBD)
  CDC-RFA-DD-27-0065 · Centers for Disease Control - NCBDDD
• NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
  PA-27-100 · National Institutes of Health · closes April 5, 2027
• Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
  PA-25-093 · National Institutes of Health · closes January 7, 2028
• CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
  PAR-27-075 · National Institutes of Health · closes November 5, 2028